<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29132415</article-id><article-id pub-id-type="pmc">5683366</article-id><article-id pub-id-type="publisher-id">2285</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2285-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Acupuncture for postprandial distress syndrome (APDS): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jing-Wen</given-names></name><address><email>yangjw0626@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Li-Wen</given-names></name><address><email>zhangliwen0929@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Guang-Xia</given-names></name><address><email>shiguangxia2008@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Yi</given-names></name><address><email>dodo_8110@aliyun.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jun</given-names></name><address><email>wangjunee@yeah.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Jing-Jie</given-names></name><address><email>13466376389@139.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Yan</given-names></name><address><email>caoyan92cy@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tu</surname><given-names>Jian-Feng</given-names></name><address><email>tujianfeng1@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shuai</given-names></name><address><email>15010541329@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Cheng</given-names></name><address><email>tancheng206@126.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>San-San</given-names></name><address><email>1187140763@qq.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Cun-Zhi</given-names></name><address><email>lcz623780@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.459365.8</institution-id><institution>Department of Acupuncture and Moxibustion, </institution><institution>Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing Key Laboratory of Acupuncture Neuromodulation, </institution></institution-wrap>No. 23 Meishuguanhou Street, Dongcheng District, Beijing, 100010 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution>Department of Traditional Chinese Medicine, Beijing Friendship Hospital, </institution><institution>Capital Medical University, </institution></institution-wrap>Beijing, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1431 9176</institution-id><institution-id institution-id-type="GRID">grid.24695.3c</institution-id><institution>Acupuncture and Moxibustion Department, </institution><institution>Dongzhimen Hospital Affiliated to Beijing University of Traditional Chinese Medicine, </institution></institution-wrap>Beijing, China </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>537</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Postprandial distress syndrome (PDS) is referred to as meal-related functional dyspepsia (FD) and causes a reduced quality of life (QoL) for patients. Several randomized controlled trials (RCTs) have suggested that acupuncture is an effective treatment for FD, but few studies were particularly for PDS. This pilot study was designed to determine the feasibility and efficacy of acupuncture in patients with PDS characterized by postprandial fullness and early satiation according to the Rome III criteria.</p></sec><sec><title>Methods</title><p id="Par2">This is a multi-center, two-arm, blinded (participants), pilot RCT. Forty-two participants who meet the inclusion criteria will be randomly assigned to the verum acupuncture group or minimal acupuncture group in a 1:1 ratio. Both treatments consist of 12 sessions of 20&#x000a0;min duration over four weeks (three sessions per week). The primary outcome measurement is the proportion of persons who improve as assessed using the global outcome by the overall treatment effect (OTE) at end-of-treatment (EOT) (four weeks after randomization). Global assessment at weeks 8 and 16 after randomization is one of the secondary outcomes. The other secondary outcomes including symptoms, disease-specific QoL, and depression and anxiety will be assessed at weeks 4, 8, and 16 after randomization.</p></sec><sec><title>Discussion</title><p id="Par3">This pilot study will help determine the feasibility and efficacy of acupuncture in patients with PDS.</p></sec><sec><title>Trial registration</title><p id="Par4">ISRCTN Registry, <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN18135146?q=18135146&#x00026;filters=&#x00026;sort=&#x00026;offset=1&#x00026;totalResults=1&#x00026;page=1&#x00026;pageSize=10&#x00026;searchType=basic-search">ISRCTN18135146</ext-link>. Registered on 7 July 2016.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-017-2285-9) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Postprandial distress syndrome</kwd><kwd>Functional dyspepsia</kwd><kwd>Acupuncture</kwd><kwd>Randomized controlled trial</kwd><kwd>Minimal acupuncture</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p id="Par15">Functional dyspepsia (FD) is classified into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) based on accumulating epidemiological and pathophysiological data [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. PDS is a characterized by postprandial fullness and early satiation [<xref ref-type="bibr" rid="CR2">2</xref>], in the absence of any organic, systemic, or metabolic disease that likely explains the symptoms. Both in the general population and in patients, the most common symptom is postprandial fullness (68&#x02013;86%)&#x02014;the main symptom of PDS [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. PDS might have a higher prevalence of impaired gastric accommodation than EPS [<xref ref-type="bibr" rid="CR1">1</xref>]. Only a few randomized controlled trials (RCTs) were conducted to examine the treatment responses of PDS and EPS, though testing responses to different FD subgroup are urgently needed [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par16">This condition is not a life-threatening disease [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], although patients suffer from a reduced quality of life (QoL) [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. According to a ten-year follow-up study, up to 40% of people with the condition consult a primary care physician [<xref ref-type="bibr" rid="CR12">12</xref>]. PDS is associated with higher rates of absenteeism and lower productivity at work [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Employed people with dyspepsia possibly have a reduced potential productivity of 35.7% [<xref ref-type="bibr" rid="CR15">15</xref>]. In the United States, costs associated with FD in 2009 were in excess of US$18 billion, meaning that it has substantial financial implications for patients, healthcare organizations, and society [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par17">Given the limited efficacy of the major of current treatments for FD, it is not surprising that alternative therapies including acupuncture are attractive to both patients and practitioners [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Several RCTs have suggested that acupuncture is an effective treatment for FD [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]; however, the studies designed especially for PDS with acupuncture treatment were few. Only a retrospective analysis of acupuncture for FD showed that PDS patients responded better to the acupuncture therapies compared with EPS [<xref ref-type="bibr" rid="CR22">22</xref>] and acupuncture was not more effective in epigastric pain and epigastric burning (the main symptoms of EPS) than sham acupuncture [<xref ref-type="bibr" rid="CR23">23</xref>]. The differences in pathological mechanisms of PDS and EPS have been controversial and it remained indistinct whether different treatments are needed for EPS and PDS [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, further RCTs to evaluate the treatment responses of PDS are needed. We designed this study to determine the feasibility and efficacy of acupuncture in patients with PDS.</p></sec><sec id="Sec2"><title>Methods/Design</title><sec id="Sec3"><title>Study design</title><p id="Par18">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the study design. This multi-center, two-arm, blinded (participants), pilot RCT will be conducted at three centers: Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University; Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine; and Beijing Friendship Hospital Affiliated to Capital Medical University in China. The participants will be recruited primarily through advertisements on hospital social media, general practitioners, and public community service centers. This trial was registered with ISRCTN at Current Controlled Trials (ISRCTN18135146, Additional&#x000a0;file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>) and followed the Declaration of Helsinki Good Clinical Practice guidelines for trial conduct. The study protocol (version 1.0, 18 January 2016) has been approved by the Research Ethics Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (reference: 2016BL-011-01) and conformed to CONSORT [<xref ref-type="bibr" rid="CR24">24</xref>] and STRICTA guidelines [<xref ref-type="bibr" rid="CR25">25</xref>] for acupuncture studies (Additional&#x000a0;file&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>). Before randomization, all participants will be requested to provide written informed consent.<fig id="Fig1"><label>Fig. 1</label><caption><p>
<italic>Flowchart</italic> of trial procedures</p></caption><graphic xlink:href="13063_2017_2285_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec4"><title>Eligibility</title><sec id="Sec5"><title>Inclusion criteria</title><p id="Par19">
<list list-type="order"><list-item><p id="Par20">Aged 18&#x02013;65 years (either sex)</p></list-item><list-item><p id="Par21">Meeting the Rome III PDS criteria</p></list-item><list-item><p id="Par22">Normal esophagogastroduodenoscopy results within one year</p></list-item><list-item><p id="Par23">No other treatments received during the study</p></list-item><list-item><p id="Par24">Willing to sign written informed consent</p></list-item></list>
</p></sec><sec id="Sec6"><title>Exclusion criteria</title><p id="Par25">
<list list-type="order"><list-item><p id="Par26">Presence of serious structural disease (disease of heart, lung, liver, or kidney)</p></list-item><list-item><p id="Par27">Signs of irritable bowel syndrome</p></list-item><list-item><p id="Par28">Surgery related with the gastrointestinal tract</p></list-item><list-item><p id="Par29">Severe coagulopathy</p></list-item><list-item><p id="Par30">Taking drugs that might affect dyspepsia, such as anti-secretary drugs, antacids, prokinetics, non-steroidal anti-inflammatory drugs, and antidepressants two weeks before participating in the trial</p></list-item><list-item><p id="Par31">Difficulties in attending the trial, such as serious mental illness, dementia, or illiteracy</p></list-item><list-item><p id="Par32">Drug or alcohol abuse</p></list-item><list-item><p id="Par33">Pregnant or breastfeeding</p></list-item></list>
</p></sec><sec id="Sec7"><title>Randomization and allocation concealment</title><p id="Par34">All participants who meet the inclusion criteria will be randomly assigned to the verum acupuncture group or minimal acupuncture group in a 1:1 ratio according to a randomization sequence generated using SPSS19.0 software. The randomization sequence will be prepared by a professional statistician, who will not be involved in assessment or treatment of participants. An independent clinical trials researcher will implement the allocation schedule using a centralized telephone randomization procedure. The random number will be assigned after the participants have met all inclusion criteria and completed baseline assessment. The Clinical Research Coordinator (CRC) will be responsible for enrolling participants, obtaining informed consent and requesting randomization.</p></sec><sec id="Sec8"><title>Blinding</title><p id="Par35">The acupuncturists who deliver the treatment to the participants will not be blind to treatment allocation. Blinding of acupuncturists is not possible due to the nature of acupuncture. Participants and all other investigators will be blinded to the treatment allocation, including the data analysis and outcome assessors. Treatment groups will be identified as Group A and Group B during the statistical analysis of all the data for data analysis.</p></sec><sec id="Sec9"><title>Intervention</title><p id="Par36">The treatment protocol for acupuncture was developed using the clinical experience of acupuncture experts for reference. Verum acupuncture and minimal acupuncture will be performed by certified acupuncturists who hold a Chinese medicine practitioner license from the Ministry of Health of the People&#x02019;s Republic of China and worked for at least three years in clinics. Before the trial, all the acupuncturists will be required to take special training to acquire a full understanding of the performance of treatment and receive a brochure showing detailed information on the standardized operation. The training included the method of the location of acupoints and non-acupoints as well as manipulation of acupuncture and minimal acupuncture. We will use sterile needles (Huatuo disposable acupuncture needle) in sizes of 0.25&#x02009;&#x000d7;&#x02009;25&#x000a0;mm or 0.25&#x02009;&#x000d7;&#x02009;40&#x000a0;mm. Both the verum acupuncture and minimal acupuncture treatments consist of 12 sessions of 20&#x000a0;min duration over four weeks (three sessions per week). The use of other treatments related to PDS, such as prokinetic agents or tricyclic antidepressants, will not be allowed.</p></sec><sec id="Sec10"><title>Verum acupuncture</title><p id="Par37">Participants randomized to the verum acupuncture group will undergo treatment lying down with needles inserted at the selected acupuncture points. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> describe the verum acupuncture point prescription. Acupuncturists will be required to achieve the typical acupuncture sensation of De qi and needles will be stimulated manually for at least 30&#x000a0;s at every acupoint and retained in place for 20&#x000a0;min. De qi, literally meaning &#x0201c;arrival of energy,&#x0201d; is referred to as a sensation of numbness or distension and may be one indication that acupuncture is exerting its beneficial effects.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Location of acupoints in verum acupuncture group</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Acupoints</th><th>Location</th></tr></thead><tbody><tr><td>Baihui (DU20)</td><td>On the midline of the head, 7 cun<sup>a</sup> directly above the midpoint of the posterior hairline</td></tr><tr><td>Zhongwan (RN12)</td><td>On the anterior midline, 4 cun above the umbilicus</td></tr><tr><td>Tianshu (ST25)</td><td>On the same level of the umbilicus and 2 cun lateral to the anterior midline</td></tr><tr><td>Qihai (RN6)</td><td>On the anterior midline, 1.5 cun below the umbilicus</td></tr><tr><td>Neiguan (PC6)</td><td>On the line joining Daling and Quze, between the tendons of palmaris longus and flexor carpi radialis, 2 cun above the transverse crease of the wrist</td></tr><tr><td>Danzhong (RN17)</td><td>On the anterior midline, on the level of the fourth intercostal space, at the midpoint of the line joining the two nipples</td></tr><tr><td>Zusanli (ST36)</td><td>3 cun directly below Dubi (ST35) and one finger-breadth lateral to the anterior border of the tibia</td></tr><tr><td>Gongsun (SP4)</td><td>On the medial side of the foot, in the depression anterior and inferior to the first metatarsal bone, at the junction of the red and white skin</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>One &#x0201c;cun&#x0201d; is defined as the width of the interphalangeal joint of patient&#x02019;s thumb</p></table-wrap-foot></table-wrap>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Location of acupoints in verum acupuncture group</p></caption><graphic xlink:href="13063_2017_2285_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec11"><title>Minimal acupuncture</title><p id="Par38">Non-acupoints with a superficial puncture (2&#x000a0;mm in depth) will be performed in minimal acupuncture group, without considering a needle sensation and manual stimulation. The locations of non-acupoints are away from any acupoints or meridians and shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. The treatment disposal will be the same as in the verum acupuncture group.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Location of non-acupoints in minimal acupuncture group</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Non-acupoints</th><th>Location</th></tr></thead><tbody><tr><td>NP1</td><td>In the middle of Jiaosun (SJ20) and Shuaigu (GB8) points</td></tr><tr><td>NP2</td><td>2.0 cun<sup>a</sup> above the anterior superior iliac spine</td></tr><tr><td>NP3</td><td>2.0 cun below the umbilicus and 1.0 cun lateral to the anterior midline</td></tr><tr><td>NP4</td><td>In the middle of the medial epicondyle of the humerus and the styloid process of ulna</td></tr><tr><td>NP5</td><td>3.0 cun below Yanglingquan (GB34), between the gallbladder and bladder meridian</td></tr><tr><td>NP6</td><td>In the middle of Qiuxu (GB40) and Jiexi (ST41) points</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>One &#x0201c;cun&#x0201d; is defined as the width of the interphalangeal joint of patient&#x02019;s thumb</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Location of non-acupoints in minimal acupuncture group</p></caption><graphic xlink:href="13063_2017_2285_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec12"><title>Outcomes</title><p id="Par39">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> summarizes the outcomes and the time-points of data collection during the trial.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Time to visit and data collection</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Outcomes</th><th rowspan="2">Baseline</th><th colspan="4">Treatment</th><th colspan="3">Follow-up</th></tr><tr><th>1&#x000a0;weeks</th><th>2&#x000a0;weeks</th><th>3&#x000a0;weeks</th><th>4&#x000a0;weeks</th><th>8&#x000a0;weeks</th><th>12&#x000a0;weeks</th><th>16&#x000a0;weeks</th></tr></thead><tbody><tr><td colspan="9">Patients</td></tr><tr><td>&#x02003;Informed consent</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Screening</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Sign informed consent</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Randomization</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="9">Primary outcome</td></tr><tr><td>&#x02003;OTE</td><td/><td/><td/><td/><td>&#x000d7;</td><td/><td/><td/></tr><tr><td colspan="9">Second outcome</td></tr><tr><td>&#x02003;OTE</td><td/><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td/><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td></tr><tr><td>&#x02003;Symptoms</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td></tr><tr><td>&#x02003;NPI</td><td>&#x000d7;</td><td/><td/><td/><td>&#x000d7;</td><td>&#x000d7;</td><td/><td>&#x000d7;</td></tr><tr><td>&#x02003;HADS</td><td>&#x000d7;</td><td/><td/><td/><td>&#x000d7;</td><td>&#x000d7;</td><td/><td>&#x000d7;</td></tr><tr><td>&#x02003;Adverse events</td><td/><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>OTE</italic> overall treatment effect, <italic>NPI</italic> Nepean Dyspepsia Index, <italic>HADS</italic> Hospital Anxiety Depression Scale</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Primary outcome measurement</title><p id="Par40">The primary outcome is the responder rate based on the overall treatment effect (OTE) at end-of-treatment (EOT, four weeks after randomization) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The patient will be asked to decide whether symptoms have changed compared with pre-treatment using a Likert scale. The question will be asked &#x0201c;How were your gastric symptoms during the past week in comparison with the baseline period?&#x0201d; The seven-point Likert scale consists of &#x0201c;extremely improved,&#x0201d; &#x0201c;improved,&#x0201d; &#x0201c;slightly improved,&#x0201d; &#x0201c;not changed,&#x0201d; &#x0201c;slightly aggravated,&#x0201d; &#x0201c;aggravated,&#x0201d; and &#x0201c;extremely aggravated&#x0201d; [<xref ref-type="bibr" rid="CR27">27</xref>]. Patients who are &#x0201c;extremely improved&#x0201d; or &#x0201c;improved&#x0201d; of the OTE will be considered responders. OTE has been used as the primary and secondary outcomes measure in several trials with FD [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. The advantage of this endpoint is that it closely resembles the way physicians evaluate treatment benefit in clinical practice, but the main disadvantage is the inherent recall of pre-treatment symptom severity which may lead to bias [<xref ref-type="bibr" rid="CR26">26</xref>].</p></sec></sec><sec id="Sec14"><title>Secondary outcome measurements</title><sec id="Sec15"><title>Global assessment at other time-points</title><p id="Par41">The primary outcome measurement is the OTE at the EOT; however, responder rate based on OTE will also be measured weekly (during the treatment) and at weeks 8, 12, and 16 after randomization with a seven-point Likert scale [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec16"><title>Symptoms assessment</title><p id="Par42">The eight dyspepsia symptoms including postprandial fullness, early satiation, upper abdominal bloating, epigastric pain, epigastric burning, nausea, vomit, and belching will be assessed at baseline, once a week for four weeks in the treatment period and at weeks 8, 12, and 16 after randomization. The severity of each symptom is rated as a four-item questionnaire: asymptomatic (0 points); mild (1 point); moderate (2 points); or severe (3 points) [<xref ref-type="bibr" rid="CR20">20</xref>]. A higher score reflects a more serious disease state.</p></sec><sec id="Sec17"><title>Disease-specific QoL assessment</title><p id="Par43">QoL will be assessed at baseline and at weeks 4, 8, and 16 after randomization using the 25-item Nepean Dyspepsia Index (NDI) [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>], which measures the specific life quality of FD patients in four domains: interference (13 items); know/control (seven items); eat/drink (three items); and sleep/disturb (two items). The scores are measured using a five-point Likert scale that ranges from &#x0201c;not at all&#x0201d; to &#x0201c;extremely,&#x0201d; with higher scores indicating a better QoL.</p></sec><sec id="Sec18"><title>Depression and anxiety assessment</title><p id="Par44">Depression and anxiety symptoms will be assessed by the Hospital Anxiety Depression Scale (HADS), which has been validated for in a wide variety of general medical patients. It is a self-report inventory consisting of 14 questions, seven of which relate to anxiety symptoms and seven to depressive symptoms. A higher score reflects a more serious state of depression and anxiety. The participants will complete the HADS at baseline and at weeks 4, 8, and 16 after randomization.</p></sec><sec id="Sec19"><title>Adverse events</title><p id="Par45">Any adverse events related to acupuncture will be monitored and recorded by participants or acupuncturists using a designed questionnaire. Possible adverse events are local bleeding, redness, itching at the sites of needle insertion, and dizziness throughout treatment. Adverse events will be assessed by outcome assessors weekly during the treatment period.</p></sec><sec id="Sec20"><title>Data management</title><p id="Par46">All researchers including therapists, data collector, data entry clerks, data manager, statistician, and outcome assessors will receive training regarding the data management. Upon conclusion of the treatment period, all participant data will be completed and recorded on the original case report forms (CRFs). The data will be entered into Excel spreadsheets by two separate data entry clerks, following which the data manager will compare the accuracy of the two datasets. If any differences are noted, corrections will be made according to the original CRFs.</p><p id="Par47">All paper files related to the research will be saved and electronic documents will be stored in a password-protected computer. All research documents, including both the paper files and electronic documents, will be preserved for at least five years after publication. If readers have any questions regarding our published data, they will be permitted to contact our first author or corresponding author to ask for the original data. The private information of patients including name, age, and telephone number, will be protected and never disclosed to anyone.</p><p id="Par48">In addition, we will establish an independent Data and Safety Monitoring Board (DSMB) to review and interpret data generated from the study (Additional&#x000a0;file&#x000a0;<xref rid="MOESM3" ref-type="media">3</xref>). The primary objective of DSMB is to ensure the integrity of the research data. The DSMB will review the progress of the trial and decide on any premature closure of the study.</p></sec><sec id="Sec21"><title>Sample size</title><p id="Par49">This pilot study aims to assess the efficacy of acupuncture for PDS as well as the feasibility of a further large clinical trial. We did not perform a sample size calculation for this pilot study, but will use a convenience sample based on the known availability of study participants at the three sites. We estimate that we will be able to enroll 42 individuals, 14 in each center, for this pilot study. Both the verum acupuncture and minimal acupuncture groups will contain 21 eligible participants. The outcomes of this study will facilitate the calculation of the appropriate sample size for further RCTs.</p></sec><sec id="Sec22"><title>Statistical analysis</title><p id="Par50">The statistical analysis will be performed by an independent statistician who is blinded to group allocation using SPSS 19.0 (IBM SPSS Statistics, New York, NY, USA). All efficacy analyses will be performed using the intent-to-treat (ITT) and per-protocol (PP) population. For ITT analysis, the population will consist of all participants who have been randomized and received acupuncture treatment at least once and the last observation carried forward rule will be applied. The PP analysis will include only those participants who will complete more than ten acupuncture treatments and have no major protocol violations (taking other drugs during the trial, not completing the CRF as required, etc.). The categorical data will be described as percentage (n %) and continuous data using mean&#x02009;&#x000b1;&#x02009;standard deviations. Continuous variables will be analyzed using the t-test and categorical variables using the Chi-square (&#x003c7;<sup>2</sup>) test. The statistical significance level will be set at 0.05 (two-sided) with 95% confidence intervals.</p></sec></sec></sec><sec id="Sec23"><title>Discussion</title><p id="Par51">People with PDS have a normal life expectancy, but the impact on QoL is notable. This pilot study has been designed, therefore, to evaluate whether acupuncture will improve the symptoms of PDS (postprandial fullness and early satiation) and be a feasible therapy for clinical treatment.</p><p id="Par52">Whether different treatments are needed for EPS and PDS is indistinct and in the previous RCTs, only acotiamide, a new drug for the treatment of FD, has been certified to be effective in PDS but not in EPS [<xref ref-type="bibr" rid="CR30">30</xref>]. We are the first RCT designed for PDS with acupuncture treatment. Our study meets methodological theory of adequate randomization and allocation concealment, blinding of outcome assessors and statisticians, and applying ITT analysis strategy. In addition to PDS symptoms and disease-specific QoL, the depression and anxiety status of the patients will also be measured in our study.</p><p id="Par53">The primarily limitation of our trial is that acupuncturists could not be blinded, but we provided special training and provide a brochure to minimize bias. Second, in consideration of the ethical requirements and patient compliance, a blank control group was not designed and the influence of self-healing could not be excluded from the acupuncture effect. This pilot RCT aims to evaluate the feasibility and efficacy of acupuncture for PDS and, if effective, a further large clinical will be conducted.</p><sec id="Sec24"><title>Trial status</title><p id="Par54">This trial is currently recruiting participants.</p></sec></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec25"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13063_2017_2285_MOESM1_ESM.pdf"><label>Additional file 1:</label><caption><p>Trial registration: Acupuncture for postprandial distress syndrome (PDS). (PDF 23&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13063_2017_2285_MOESM2_ESM.pdf"><label>Additional file 2:</label><caption><p>SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.* (PDF 192&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13063_2017_2285_MOESM3_ESM.jpg"><label>Additional file 3:</label><caption><p>DSMB of Acupuncture for postprandial distress syndrome. (JPG 640&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>EOT</term><def><p id="Par5">End-of-treatment</p></def></def-item><def-item><term>EPS</term><def><p id="Par6">Epigastric pain syndrome</p></def></def-item><def-item><term>FD</term><def><p id="Par7">Functional dyspepsia</p></def></def-item><def-item><term>HADS</term><def><p id="Par8">Hospital Anxiety Depression Scale</p></def></def-item><def-item><term>ITT</term><def><p id="Par9">Intent-to-treat</p></def></def-item><def-item><term>NDI</term><def><p id="Par10">Nepean Dyspepsia Index</p></def></def-item><def-item><term>OTE</term><def><p id="Par11">Overall treatment effect</p></def></def-item><def-item><term>PDS</term><def><p id="Par12">Postprandial distress syndrome</p></def></def-item><def-item><term>PP</term><def><p id="Par13">Per-protocol</p></def></def-item><def-item><term>QoL</term><def><p id="Par14">Quality of life</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13063-017-2285-9) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par55">This work was supported by Beijing Municipal Science &#x00026; Technology Commission (No. Z161100000516007). The funder has no role in the design or conduct of the trial.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par56">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>CZL, GXS, LWZ, and YC conceived of the study and initiated the study design. JWY, YD, JW, JJZ, CT, SSC, and JFT helped with its implementation. LWZ, GXS, and SZ drafted the manuscript. JWY revised the manuscript. CZL sought funding and ethical approval. All authors contributed to the revision of the study protocol and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par57">The central ethics committee Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University has approved the study protocol in all the centers (reference: 2016BL-011-01). Before randomization, all participants will be requested to provide written informed consent.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par58">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par59">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par60">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2013</year><volume>10</volume><issue>3</issue><fpage>134</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2013.14</pub-id><pub-id pub-id-type="pmid">23399526</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Holtmann</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Malagelada</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Functional gastroduodenal disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><issue>5</issue><fpage>1466</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.11.059</pub-id><pub-id pub-id-type="pmid">16678560</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piessevaux</surname><given-names>H</given-names></name><name><surname>De Winter</surname><given-names>B</given-names></name><name><surname>Louis</surname><given-names>E</given-names></name><name><surname>Muls</surname><given-names>V</given-names></name><name><surname>De Looze</surname><given-names>D</given-names></name><name><surname>Pelckmans</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings</article-title><source>Neurogastroenterol Motil</source><year>2009</year><volume>21</volume><issue>4</issue><fpage>378</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2009.01262.x</pub-id><pub-id pub-id-type="pmid">19222761</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Bisschops</surname><given-names>R</given-names></name><name><surname>Sarnelli</surname><given-names>G</given-names></name></person-group><article-title>Pathophysiology and treatment of functional dyspepsia</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><issue>4</issue><fpage>1239</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.05.030</pub-id><pub-id pub-id-type="pmid">15481001</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Locke</surname><given-names>GR</given-names><suffix>3rd</suffix></name><name><surname>McNally</surname><given-names>MA</given-names></name><name><surname>Halder</surname><given-names>SL</given-names></name><name><surname>Schleck</surname><given-names>CD</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Impact of functional gastrointestinal disorders on survival in the community</article-title><source>Am J Gastroenterol</source><year>2010</year><volume>105</volume><issue>4</issue><fpage>822</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/ajg.2010.40</pub-id><pub-id pub-id-type="pmid">20160713</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bailey</surname><given-names>AG</given-names></name><name><surname>Axon</surname><given-names>AT</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Effect of dyspepsia on survival: a longitudinal 10-year follow-up study</article-title><source>Am J Gastroenterol</source><year>2012</year><volume>107</volume><issue>6</issue><fpage>912</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/ajg.2012.69</pub-id><pub-id pub-id-type="pmid">22472745</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haag</surname><given-names>S</given-names></name><name><surname>Senf</surname><given-names>W</given-names></name><name><surname>H&#x004d3;user</surname><given-names>W</given-names></name><name><surname>Tagay</surname><given-names>S</given-names></name><name><surname>Grandt</surname><given-names>D</given-names></name><name><surname>Heuft</surname><given-names>G</given-names></name><etal/></person-group><article-title>Impairment of health-related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>27</volume><issue>7</issue><fpage>561</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2008.03619.x</pub-id><pub-id pub-id-type="pmid">18208571</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankhuisen</surname><given-names>R</given-names></name><name><surname>Van Herwaarden</surname><given-names>MA</given-names></name><name><surname>Heijkoop</surname><given-names>R</given-names></name><name><surname>Baron</surname><given-names>A</given-names></name><name><surname>Vermeijden</surname><given-names>R</given-names></name><name><surname>Smout</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Functional dyspepsia and irritable bowel syndrome in patients with achalasia and its association with non-cardiac chest pain and a decreased health-related quality of life</article-title><source>Scand J Gastroenterol</source><year>2009</year><volume>44</volume><issue>6</issue><fpage>687</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1080/00365520902783709</pub-id><pub-id pub-id-type="pmid">19263270</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aro</surname><given-names>P</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Agr&#x000e9;us</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>SE</given-names></name><name><surname>Bolling-Sternevald</surname><given-names>E</given-names></name><name><surname>Storskrubb</surname><given-names>T</given-names></name><etal/></person-group><article-title>Functional dyspepsia impairs quality of life in the adult population</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>33</volume><issue>11</issue><fpage>1215</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2011.04640.x</pub-id><pub-id pub-id-type="pmid">21443537</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varni</surname><given-names>JW</given-names></name><name><surname>Bendo</surname><given-names>CB</given-names></name><name><surname>Nurko</surname><given-names>S</given-names></name><name><surname>Shulman</surname><given-names>RJ</given-names></name><name><surname>Self</surname><given-names>MM</given-names></name><name><surname>Franciosi</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases</article-title><source>J Pediatr</source><year>2015</year><volume>166</volume><issue>1</issue><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2014.08.022</pub-id><pub-id pub-id-type="pmid">25241177</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Marwaha</surname><given-names>A</given-names></name><name><surname>Sood</surname><given-names>R</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis</article-title><source>Gut</source><year>2015</year><volume>64</volume><issue>7</issue><fpage>1049</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-307843</pub-id><pub-id pub-id-type="pmid">25147201</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bailey</surname><given-names>AG</given-names></name><name><surname>Cook</surname><given-names>MB</given-names></name><name><surname>Axon</surname><given-names>AT</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><issue>5</issue><fpage>957</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01080.x</pub-id><pub-id pub-id-type="pmid">17313501</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Dubois</surname><given-names>D</given-names></name><name><surname>Coulie</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Kahrilas</surname><given-names>PJ</given-names></name><name><surname>Rentz</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study</article-title><source>Clin Gastroenterol Hepatol</source><year>2005</year><volume>3</volume><issue>6</issue><fpage>543</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(05)00153-9</pub-id><pub-id pub-id-type="pmid">15952096</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brook</surname><given-names>RA</given-names></name><name><surname>Kleinman</surname><given-names>NL</given-names></name><name><surname>Choung</surname><given-names>RS</given-names></name><name><surname>Melkonian</surname><given-names>AK</given-names></name><name><surname>Smeeding</surname><given-names>JE</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Functional dyspepsia impacts absenteeism and direct and indirect costs</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><volume>8</volume><issue>6</issue><fpage>498</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2010.03.003</pub-id><pub-id pub-id-type="pmid">20304102</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>GB</given-names></name><name><surname>Mazzoleni</surname><given-names>LE</given-names></name><name><surname>Francesconi</surname><given-names>CF</given-names></name><name><surname>Balbinotto</surname><given-names>G</given-names></name><name><surname>Mazzoleni</surname><given-names>F</given-names></name><name><surname>Wortmann</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Influence of organic and functional dyspepsia on work productivity: the HEROES-DIP study</article-title><source>Value Health</source><year>2011</year><volume>14</volume><issue>5 Suppl 1</issue><fpage>S126</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2011.05.021</pub-id><pub-id pub-id-type="pmid">21839884</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacy</surname><given-names>BE</given-names></name><name><surname>Weiser</surname><given-names>KT</given-names></name><name><surname>Kennedy</surname><given-names>AT</given-names></name><name><surname>Crowell</surname><given-names>MD</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Functional dyspepsia: the economic impact to patients</article-title><source>Aliment Pharmacol Ther</source><year>2013</year><volume>38</volume><issue>2</issue><fpage>170</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/apt.12355</pub-id><pub-id pub-id-type="pmid">23725230</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Ford</surname><given-names>AC</given-names></name></person-group><article-title>Functional Dyspepsia</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>19</issue><fpage>1853</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1501505</pub-id><pub-id pub-id-type="pmid">26535514</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahner</surname><given-names>E</given-names></name><name><surname>Bellentani</surname><given-names>S</given-names></name><name><surname>Bastiani</surname><given-names>RD</given-names></name><name><surname>Tosetti</surname><given-names>C</given-names></name><name><surname>Cicala</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>G</given-names></name><etal/></person-group><article-title>A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders</article-title><source>United European Gastroenterol J</source><year>2013</year><volume>1</volume><issue>5</issue><fpage>385</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1177/2050640613499567</pub-id><pub-id pub-id-type="pmid">24917987</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>JD</given-names></name></person-group><article-title>Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>20</volume><issue>8</issue><fpage>831</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.02196.x</pub-id><pub-id pub-id-type="pmid">15479354</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KN</given-names></name><name><surname>Chung</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name></person-group><article-title>Efficacy of acupuncture treatment for functional dyspepsia: A systematic review and meta-analysis</article-title><source>Complement Ther Med</source><year>2015</year><volume>23</volume><issue>6</issue><fpage>759</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.ctim.2015.07.007</pub-id><pub-id pub-id-type="pmid">26645513</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>TT</given-names></name><name><surname>Yu</surname><given-names>SY</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>FR</given-names></name><name><surname>Tian</surname><given-names>XP</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2012</year><volume>35</volume><issue>5</issue><fpage>552</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2011.04979.x</pub-id><pub-id pub-id-type="pmid">22243034</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>CM</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Which subtype of functional dyspepsia patients responses better to acupuncture? A retrospective analysis of a randomized controlled trial</article-title><source>Forsch Komplementmed</source><year>2015</year><volume>22</volume><issue>2</issue><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">26021959</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YC</given-names></name><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Choi</surname><given-names>SM</given-names></name><name><surname>Son</surname><given-names>CG</given-names></name></person-group><article-title>Evaluation of manual acupuncture at classical and nondefined points for treatment of functional dyspepsia: a randomized-controlled trial</article-title><source>J Altern Complement Med</source><year>2009</year><volume>15</volume><issue>8</issue><fpage>879</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1089/acm.2008.0369</pub-id><pub-id pub-id-type="pmid">19678778</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>ZX</given-names></name><name><surname>Shang</surname><given-names>HC</given-names></name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title><source>Ann Intern Med</source><year>2011</year><volume>154</volume><issue>4</issue><fpage>290</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-154-4-201102150-00016</pub-id><pub-id pub-id-type="pmid">21320945</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacPherson</surname><given-names>H</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Hammerschlag</surname><given-names>R</given-names></name><name><surname>Youping</surname><given-names>L</given-names></name><name><surname>Taixiang</surname><given-names>W</given-names></name><name><surname>White</surname><given-names>A</given-names></name><etal/></person-group><article-title>Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><issue>6</issue><fpage>e1000261</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000261</pub-id><pub-id pub-id-type="pmid">20543992</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>D</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Simren</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>P</given-names></name><name><surname>Boeckxstaens</surname><given-names>G</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name></person-group><article-title>Review article: endpoints used in functional dyspepsia drug therapy trials</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>33</volume><issue>6</issue><fpage>634</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2010.04566.x</pub-id><pub-id pub-id-type="pmid">21223343</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsueda</surname><given-names>K</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name></person-group><article-title>A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia</article-title><source>Gut</source><year>2012</year><volume>61</volume><issue>6</issue><fpage>821</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-301454</pub-id><pub-id pub-id-type="pmid">22157329</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Van Zanten</surname><given-names>SJ</given-names></name><name><surname>Sinclair</surname><given-names>P</given-names></name><name><surname>Ferguson</surname><given-names>RA</given-names></name><name><surname>Escobedo</surname><given-names>S</given-names></name><name><surname>Grace</surname><given-names>E</given-names></name></person-group><article-title>Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial</article-title><source>BMJ</source><year>2002</year><volume>324</volume><issue>7344</issue><fpage>1012</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/bmj.324.7344.1012</pub-id><pub-id pub-id-type="pmid">11976244</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zanten</surname><given-names>SJV</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Barkun</surname><given-names>A</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name><name><surname>Smyth</surname><given-names>S</given-names></name><etal/></person-group><article-title>A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><issue>7</issue><fpage>1477</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.40280.x</pub-id><pub-id pub-id-type="pmid">15984968</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zanten</surname><given-names>SJV</given-names></name><name><surname>Jones</surname><given-names>MJ</given-names></name><name><surname>Verlinden</surname><given-names>M</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis</article-title><source>Am J Gastroenterol</source><year>2001</year><volume>96</volume><issue>3</issue><fpage>689</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2001.03521.x</pub-id><pub-id pub-id-type="pmid">11280535</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>van Zanten</surname><given-names>SJV</given-names></name><name><surname>Barkun</surname><given-names>AN</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Thomson</surname><given-names>AB</given-names></name><name><surname>Smyth</surname><given-names>S</given-names></name><etal/></person-group><article-title>Heartburn-dominant, uninvestigated dyspepsia: a comparison of &#x02018;PPI-start&#x02019; and &#x02018;H2-RA-start&#x02019; management strategies in primary care--the CADET-HR Study</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>21</volume><issue>10</issue><fpage>1189</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02466.x</pub-id><pub-id pub-id-type="pmid">15882239</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakil</surname><given-names>N</given-names></name><name><surname>Laine</surname><given-names>L</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Zakko</surname><given-names>SF</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials</article-title><source>Am J Gastroenterol</source><year>2008</year><volume>103</volume><issue>8</issue><fpage>1906</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">18616658</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtmann</surname><given-names>G</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Liebregts</surname><given-names>T</given-names></name><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Parow</surname><given-names>C</given-names></name></person-group><article-title>A placebo-controlled trial of itopride in functional dyspepsia</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>8</issue><fpage>832</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052639</pub-id><pub-id pub-id-type="pmid">16495395</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Ptak</surname><given-names>T</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Giguere</surname><given-names>M</given-names></name></person-group><article-title>Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials</article-title><source>Gut</source><year>2008</year><volume>57</volume><issue>6</issue><fpage>740</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/gut.2007.132449</pub-id><pub-id pub-id-type="pmid">17965059</pub-id></element-citation></ref></ref-list></back></article>